U.S. FDA approves Biogen's hemophilia A drug Eloctate

WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders.

http://feedproxy.google.com/~r/reuters/healthNews/~3/8EgzL8m1E-A/story01.htm

Source: Reuters: Health - June 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

More News: Cancer & Oncology | Food and Drug Administration (FDA) | Haemophilia | Health | Hemophilia